Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Innovative Strategies in Ischemic Heart Disease Management
Author(s): Shrilla Banerjee , Mirvat Alasnag , Marta Kałuzna-Oleksy , et al Added: 10 months ago
In this video, Dr Marta Kałużna-Oleksy is joined by Dr Mirvat Alasnag, Dr Shrilla Banerjee and Dr Michal Hawranek to discuss strategies for heart failure management, based on a presentation at the Prevention and Intervention meeting in 2024.The faculty discuss SCAD, MINOCA and holistic approaches to managing these conditions, including lifestyle factors, hypertension and diabetes. They outline… View more

Heart Failure

Intervention
Obesity in Focus: Implications for Heart Failure, Kidney Disease, and Pharmacology
Author(s): Chim C Lang , Bianca Rocca , Samira Bell Added: 1 month ago
In this short discussion, join Prof Chim Lang (University of Dundee, Dundee, UK), Guest Editor of the upcoming Special Focus on Obesity in Focus, Prof Bianca Rocca (LUM University, Casamassima, IT) and Dr Samira Bell (University of Dundee, Dundee, UK) to discover the implications of obesity on heart failure, kidney disease, and pharmacology.This conversation sets the stage for the upcoming… View more

Cardiovascular Renal Metabolic

Heart Failure
Malnutrition and Prognosis in Elderly Patients with Chronic Heart Failure
Author(s): Mohammed El-Sheikh , Nora Olsen El Caidi , Aginsha Kandiah , et al Added: 3 weeks ago

Cardiovascular Renal Metabolic

Heart Failure
AHA 25 Late-breaking Discussion: Analysis from the SURPASS-CVOT Trial
Author(s): Harriette Van Spall , Stephen Nicholls Added: 2 days ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Stephen Nicholls (Monash University, AU) to present the findings of this AHA late-breaking trial.This pre-specified analysis of the SURPASS-CVOT randomised clinical trial evaluates the comparative effects of once-weekly tirzepatide versus dulaglutide on heart failure outcomes in… View more

Cardiovascular Renal Metabolic

Heart Failure
EPCs and Innovative Strategies for Endothelial Dysfunction in Heart Failure
Author(s): Eugenio Carulli , Marialuisa Sveva Marozzi , Maria Cristina Carella , et al Added: 3 months ago

Heart Failure

Prevention & Chronic Conditions
EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease
Author(s): William Herrington Added: 1 year ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Transvenous Phrenic Nerve Stimulation in Central Sleep Apnoea/Heart Failure
Author(s): Tarek Bekfani , Joseph D Abraham , William T Abraham Added: 2 months ago

Heart Failure
ESC 25: 4 Heart Failure Trials That Will Change My Practice
Author(s): Michelle Kittleson Added: 2 months ago
ESC Congress 2025 - In this video, Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) outlines the hot-line data from the congress that are expected to have an impact on clinical practice in the heart failure space.Trials covered in detail include:REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced Ejection FractionBETAMI-DANBLOCK: Beta-Blockers after Myocardial… View more

Anticoagulation

Heart Failure
Heart Failure Treatment and Cardiac Amyloidosis
Author(s): Giorgia Panichella , Alberto Aimo , Vincenzo Castiglione , et al Added: 4 months ago

Heart Failure
CardioNerds @AHA23: SELECT: Effects of Semaglutide on Heart Disease & Stroke in Obese Patients
Author(s): A Michael Lincoff , Ahmed Ghoneem Added: 1 year ago
AHA 2023 - Investigator, Dr A Michael Lincoff (Cleveland Clinic, US) is interviewed by Dr Ahmed Ghoneem (UPMC Harrisburg, US), CardioNerds Ambassador, on the findings of the SELECT Trial (NCT03574597).SELECT is a randomised trial aiming to determine if semaglutide can reduce the risk of cardiovascular events in patients with overweight or obesity and prior cardiovascular disease. 17609 patients… View more

Guidelines & Statements

Prevention & Chronic Conditions